NO20042112L - Anvendelse av glycosider av mono- og diacylglycerol som anti-inflammatoriske midler. - Google Patents

Anvendelse av glycosider av mono- og diacylglycerol som anti-inflammatoriske midler.

Info

Publication number
NO20042112L
NO20042112L NO20042112A NO20042112A NO20042112L NO 20042112 L NO20042112 L NO 20042112L NO 20042112 A NO20042112 A NO 20042112A NO 20042112 A NO20042112 A NO 20042112A NO 20042112 L NO20042112 L NO 20042112L
Authority
NO
Norway
Prior art keywords
diacylglycerol
glycosides
mono
inflammatory agents
inflammatory
Prior art date
Application number
NO20042112A
Other languages
English (en)
Other versions
NO334587B1 (no
Inventor
Soren Brogger Christensen
Erik Larsen
Arsalan Kharazmi
Lars Porskjaer Christensen
Kirsten Brandt
Original Assignee
Danmarks Farmaceutiske Hojskol
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Danmarks Farmaceutiske Hojskol filed Critical Danmarks Farmaceutiske Hojskol
Publication of NO20042112L publication Critical patent/NO20042112L/no
Publication of NO334587B1 publication Critical patent/NO334587B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Transplantation (AREA)
NO20042112A 2001-11-21 2004-05-21 Anvendelse av glycosider av diacylglycerol som anti-inflammatoriske midler. NO334587B1 (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US33208401P 2001-11-21 2001-11-21
US34160901P 2001-12-18 2001-12-18
US35839102P 2002-02-22 2002-02-22
PCT/DK2002/000783 WO2003043613A2 (en) 2001-11-21 2002-11-21 Use of glycosides of mono- and diacylglycerol as anti-inflammatory agents

Publications (2)

Publication Number Publication Date
NO20042112L true NO20042112L (no) 2004-07-09
NO334587B1 NO334587B1 (no) 2014-04-14

Family

ID=27406836

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20042112A NO334587B1 (no) 2001-11-21 2004-05-21 Anvendelse av glycosider av diacylglycerol som anti-inflammatoriske midler.

Country Status (9)

Country Link
US (2) US7084122B2 (no)
EP (1) EP1453844B1 (no)
JP (2) JP4716655B2 (no)
CN (1) CN100469784C (no)
AU (1) AU2002366210A1 (no)
DK (1) DK1453844T3 (no)
NO (1) NO334587B1 (no)
PL (2) PL393941A1 (no)
WO (1) WO2003043613A2 (no)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0004153D0 (en) * 2000-02-23 2000-04-12 Astrazeneca Uk Ltd Novel use
GB0004151D0 (en) * 2000-02-23 2000-04-12 Astrazeneca Uk Ltd Novel use
GB0004152D0 (en) 2000-02-23 2000-04-12 Astrazeneca Uk Ltd Novel compounds
AR035700A1 (es) * 2001-05-08 2004-06-23 Astrazeneca Ab Derivados de arilheteroalquilamina, composicion farmaceutica, usos de estos derivados para la fabricacion de medicamentos, metodos de tratamiento, y proceso para la preparacion de estos derivados
SE0102640D0 (sv) * 2001-07-31 2001-07-31 Astrazeneca Ab Novel compounds
SE0203304D0 (sv) * 2002-11-07 2002-11-07 Astrazeneca Ab Novel Coumpounds
JP3914519B2 (ja) * 2003-06-06 2007-05-16 株式会社スピルリナ研究所 グリセロ糖脂質化合物を含有してなるリパーゼ活性阻害剤
US7758903B2 (en) 2003-09-12 2010-07-20 Access Business Group International Llc Cytokine modulators and related methods of use
KR101245440B1 (ko) * 2003-09-12 2013-03-19 액세스 비지니스 그룹 인터내셔날 엘엘씨 사이토킨 조절물질 및 관련된 용도
US7758902B2 (en) * 2003-09-12 2010-07-20 Access Business Group International Llc Cytokine modulators and related methods of use
JP3790767B2 (ja) * 2004-06-30 2006-06-28 森下仁丹株式会社 脂肪代謝改善組成物
US20070269540A1 (en) * 2006-05-16 2007-11-22 Morishita Jintan Co., Ltd. Fat metabolism improving agent
JP4866067B2 (ja) * 2005-11-22 2012-02-01 株式会社ファンケル メラニン産生抑制剤
US8435588B2 (en) 2005-11-23 2013-05-07 The Coca-Cola Company High-potency sweetener composition with an anti-inflammatory agent and compositions sweetened therewith
ATE524483T1 (de) * 2006-07-03 2011-09-15 Hyben Vital Licens Aps Verfahren zur herstellung eines glykosids eines mono- oder diacylglyzerinprodukts aus einem pflanzlichen material
US7547455B2 (en) * 2006-09-20 2009-06-16 Academia Sinica Cancer and inflammatory disorder treatment
KR100772078B1 (ko) 2006-11-07 2007-10-31 한국기초과학지원연구원 갈조류 지충이로부터 분리된 신규모노갈락토실디아실글리세롤 화합물
JPWO2008108001A1 (ja) * 2007-03-02 2010-06-10 株式会社東洋新薬 ガラクト脂質
HRP20150593T1 (hr) * 2007-12-21 2015-07-31 Finzelberg Gmbh & Co. Kg Pripravci s ekstraktima šipka i postupak proizvodnje ekstrakta šipka
NZ567712A (en) * 2008-04-24 2010-11-26 Fonterra Cooperative Group Ltd Compositions and methods for maintaining bone health or reducing bone loss
US9173912B2 (en) 2008-05-06 2015-11-03 Finzelberg Gmbh & Co. Kg Cistus extract containing enriched secondary plant ingredients
EP2349281A1 (en) 2008-10-30 2011-08-03 Hyben Vital Licens ApS Composition comprising a glycoside of a mono- or diacyiglycerol compound and an oil rich in n-3 polyunsaturated fatty acids, a method of producing the composition and use of the composition
DK177605B1 (en) 2010-03-16 2013-11-18 Hyben Vital Licens Aps Compositions of rose hips enriched with seeds of rose hips and their use as anti-inflammatory natural medicine for alleviating/reducing symptoms associated with inflammation and joint diseases such as arthritis and/or osteo-arthritis
EP2389816A1 (en) 2010-05-25 2011-11-30 Nestec S.A. Synergistic antioxidant composition
MX2012015059A (es) * 2010-06-25 2013-04-03 Horphag Res Ip Pre Ltd Composicion para mejorar el bienestar sexual.
TWI558403B (zh) * 2013-06-04 2016-11-21 中央研究院 富含半乳糖脂之植物萃取物及其用途
JP6339426B2 (ja) * 2014-06-30 2018-06-06 株式会社ファンケル グリセロ糖脂質を含有する組成物の製造方法及びグリセロ糖脂質含有組成物
SG11201811595SA (en) 2016-06-27 2019-01-30 Ohio State Innovation Foundation Liponucleotide-based therapy for ards
CN106983763B (zh) * 2017-04-25 2021-04-20 中国海洋大学 单半乳糖基二酰基甘油酯及其制备方法与用途
CN110201026B (zh) * 2019-07-15 2021-09-24 青岛农业大学 一种非抗生素型结肠炎修复制剂
KR102780726B1 (ko) * 2022-12-30 2025-03-13 주식회사 미래생명자원 테트라셀미스 츄이로부터 분리한 신규 화합물 및 이의 용도

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05271270A (ja) 1992-03-27 1993-10-19 Nippon Paper Ind Co Ltd 糖ーグリセロール誘導体とその合成法
JP3298723B2 (ja) * 1993-03-30 2002-07-08 武田食品工業株式会社 発癌プロモーション抑制組成物
WO1994024984A2 (en) 1993-04-30 1994-11-10 Winget Rodner R Anti-inflammatory compositions containing eicosapentaenoic acid bearing monogalactosyldiacylglycerol and methods relating thereto
JPH07149786A (ja) 1993-11-26 1995-06-13 Sagami Chem Res Center グリセロ糖脂質及び発癌プロモーター阻害剤
CA2142153A1 (en) 1994-03-04 1995-09-05 Jacques Banville Sulfated .beta.-glycolipid derivatives as cell adhesion inhibitors
US5663151A (en) * 1994-03-04 1997-09-02 Bristol-Myers Squibb Company Sulfated α-glycolipid derivatives as cell adhesion inhibitors
US5486536A (en) * 1994-08-15 1996-01-23 The Regents Of The University Of Michigan Sulfatides as anti-inflammatory compounds
DE19634021A1 (de) 1996-08-23 1998-02-26 Beiersdorf Ag Antiadhäsive Glycoglycerolipide
DE19634019A1 (de) * 1996-08-23 1998-02-26 Beiersdorf Ag Gegen Mikroogranismen, Viren, Parasiten und Protozoen wirksame Glycoglycerolipide
DE19700774A1 (de) 1997-01-13 1998-07-16 Hoechst Ag Antiadhäsive Sulfatid-Mimetika
US6024960A (en) * 1998-04-17 2000-02-15 Otto Torbjorn Hansen And Marianne Hansen Rose-hip formulations as anti-inflammatory natural medicine for alleviating/reducing symptoms associated with inflammation and arthritis

Also Published As

Publication number Publication date
AU2002366210A1 (en) 2003-06-10
US20050049205A1 (en) 2005-03-03
EP1453844B1 (en) 2013-11-20
US20030139350A1 (en) 2003-07-24
WO2003043613A2 (en) 2003-05-30
EP1453844A2 (en) 2004-09-08
JP2010215660A (ja) 2010-09-30
CN1606563A (zh) 2005-04-13
WO2003043613A3 (en) 2004-03-25
NO334587B1 (no) 2014-04-14
JP2005513023A (ja) 2005-05-12
CN100469784C (zh) 2009-03-18
US7084122B2 (en) 2006-08-01
PL213644B1 (pl) 2013-04-30
DK1453844T3 (da) 2014-02-10
PL393941A1 (pl) 2011-06-20
JP4716655B2 (ja) 2011-07-06
AU2002366210A8 (en) 2003-06-10
PL370888A1 (en) 2005-05-30

Similar Documents

Publication Publication Date Title
DK1453844T3 (da) Anvendelse af glycosider af mono- og diacylglycerol som anti-inflammatoriske midler
NO20014412D0 (no) Forbindelser nyttige som anti-inflammatoriske midler
NO20033969L (no) Triazolpyridiner som anti-inflammatoriske midler
NO20035087L (no) Anvendelse av HMG fragment som anti-inflammatoriske midler
NO20010964D0 (no) Alkynyl-substituerte quinolin-2-onderivater nyttige som anticancer midler
NO20014759D0 (no) C(7)-estersubstituerte taksaner som antitumormidler
NO20026195L (no) Substituerte triazolpyrimidiner som anticancermidler
NO20042680L (no) Fremgangsmater for fremstilling av O-demetylvenflaxine
NO20042955L (no) Substituerte fenylaftalener som estrogene midler
NO20042279L (no) Kinazolinderivater som antitumormidler
NO20042288L (no) Kinazolinderivater som antitumormidler
NO20030550D0 (no) 17<beta>-karbotioat 17<alfa>-arylkarbonyloksyandrostanderivat som anti-inflammatoriske midler
NO20041339L (no) Spiro-hydantoin-forbindelser anvendelige som anti-inflammatoriske midler
NO20013671L (no) Substituerte bisycliske derivater nyttige som anticancer midler
CY2009001I2 (el) Νεα μορφη κρυσταλλου του παραγωγου πυρρολιδυλοθειοκαρβαπενεμης
MXPA03009361A (es) Compuestos de urea utilies como agentes anti-inflamatorios.
DK1429607T3 (da) Delta-1-pyrroliner som pesticider
DK1086097T3 (da) Sulfonylbenzenforbindelser som anti-inflammatoriske/analgetiske midler
NO20012526D0 (no) Sammensetninger som innbefatter cefuroksimaksetil
ITMI20001883A0 (it) Procedimento integrato per la preparazione di epossidi
PT1372937E (pt) Moldes de sopragem de dupla cavidade de múltiplas gotas
NO20012965D0 (no) Sulfonyloksazolaminer som terapeutisk aktive forbindelser
NO20014753L (no) C(10)-karbonatsubstituerte taxaner som antitumormidler
DK1075471T3 (da) Idolylderivater som serotonerge midler
ITMI20001695A0 (it) Procedimento per la preparazione di composizioni organico-sili-coniche.

Legal Events

Date Code Title Description
CREP Change of representative

Representative=s name: PLOUGMANN & VINGTOFT, POSTBOKS 1003 SENTRUM, 0104

MK1K Patent expired